NCT03983057 2026-02-11
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
Phase 2 Completed
Clinical Trials
10 trialsNCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05223231 2026-02-02
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT04191421 2025-08-22
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
Phase 1/2 Completed
NCT03104699 2025-07-30
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus Inc.
Phase 1/2 Completed
NCT01351103 2025-06-13
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
Phase 1 Completed
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed